nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100A12—myometrium—ovarian cancer	0.0157	0.0536	CbGeAlD
Olopatadine—S100A2—epithelium—ovarian cancer	0.0153	0.0521	CbGeAlD
Olopatadine—S100A2—uterine cervix—ovarian cancer	0.0152	0.0517	CbGeAlD
Olopatadine—S100A1—decidua—ovarian cancer	0.0133	0.0454	CbGeAlD
Olopatadine—S100A1—endometrium—ovarian cancer	0.0126	0.0431	CbGeAlD
Olopatadine—S100A13—epithelium—ovarian cancer	0.0125	0.0426	CbGeAlD
Olopatadine—S100A12—epithelium—ovarian cancer	0.0123	0.042	CbGeAlD
Olopatadine—S100A12—uterine cervix—ovarian cancer	0.0122	0.0417	CbGeAlD
Olopatadine—S100A12—decidua—ovarian cancer	0.0116	0.0397	CbGeAlD
Olopatadine—S100A2—female reproductive system—ovarian cancer	0.0114	0.0387	CbGeAlD
Olopatadine—S100A1—female reproductive system—ovarian cancer	0.0105	0.0357	CbGeAlD
Olopatadine—S100A13—gonad—ovarian cancer	0.0104	0.0354	CbGeAlD
Olopatadine—S100A2—female gonad—ovarian cancer	0.0103	0.0352	CbGeAlD
Olopatadine—S100A2—vagina—ovarian cancer	0.0103	0.035	CbGeAlD
Olopatadine—S100A13—female reproductive system—ovarian cancer	0.00928	0.0317	CbGeAlD
Olopatadine—S100A2—testis—ovarian cancer	0.00917	0.0313	CbGeAlD
Olopatadine—S100A12—bone marrow—ovarian cancer	0.00864	0.0295	CbGeAlD
Olopatadine—S100A13—female gonad—ovarian cancer	0.00844	0.0288	CbGeAlD
Olopatadine—S100A1—testis—ovarian cancer	0.00844	0.0288	CbGeAlD
Olopatadine—S100A12—female gonad—ovarian cancer	0.00833	0.0284	CbGeAlD
Olopatadine—S100A12—vagina—ovarian cancer	0.00828	0.0282	CbGeAlD
Olopatadine—S100A13—testis—ovarian cancer	0.00749	0.0255	CbGeAlD
Olopatadine—S100A12—testis—ovarian cancer	0.00739	0.0252	CbGeAlD
Olopatadine—S100A1—lymph node—ovarian cancer	0.00612	0.0209	CbGeAlD
Olopatadine—S100A13—lymph node—ovarian cancer	0.00543	0.0185	CbGeAlD
Olopatadine—S100A12—lymph node—ovarian cancer	0.00536	0.0183	CbGeAlD
Olopatadine—S100B—lymph node—ovarian cancer	0.00529	0.018	CbGeAlD
Olopatadine—HRH1—myometrium—ovarian cancer	0.00318	0.0108	CbGeAlD
Olopatadine—HRH1—epithelium—ovarian cancer	0.00249	0.00851	CbGeAlD
Olopatadine—HRH1—uterine cervix—ovarian cancer	0.00247	0.00844	CbGeAlD
Olopatadine—HRH1—decidua—ovarian cancer	0.00236	0.00804	CbGeAlD
Olopatadine—HRH1—endometrium—ovarian cancer	0.00224	0.00763	CbGeAlD
Olopatadine—HRH1—female reproductive system—ovarian cancer	0.00185	0.00632	CbGeAlD
Olopatadine—HRH1—female gonad—ovarian cancer	0.00169	0.00575	CbGeAlD
Olopatadine—HRH1—vagina—ovarian cancer	0.00168	0.00572	CbGeAlD
Olopatadine—HRH1—testis—ovarian cancer	0.0015	0.0051	CbGeAlD
Olopatadine—CYP3A4—female reproductive system—ovarian cancer	0.00143	0.00489	CbGeAlD
Olopatadine—HRH1—lymph node—ovarian cancer	0.00108	0.0037	CbGeAlD
Olopatadine—Dyspnoea—Melphalan—ovarian cancer	0.000974	0.0033	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000963	0.00327	CcSEcCtD
Olopatadine—Fatigue—Topotecan—ovarian cancer	0.000962	0.00326	CcSEcCtD
Olopatadine—Pain—Topotecan—ovarian cancer	0.000954	0.00324	CcSEcCtD
Olopatadine—Dry eye—Epirubicin—ovarian cancer	0.00095	0.00322	CcSEcCtD
Olopatadine—Epistaxis—Paclitaxel—ovarian cancer	0.000949	0.00322	CcSEcCtD
Olopatadine—Infection—Vinorelbine—ovarian cancer	0.000948	0.00322	CcSEcCtD
Olopatadine—Sinusitis—Paclitaxel—ovarian cancer	0.000944	0.0032	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000943	0.0032	CcSEcCtD
Olopatadine—Fatigue—Melphalan—ovarian cancer	0.000942	0.00319	CcSEcCtD
Olopatadine—Dermatitis contact—Doxorubicin—ovarian cancer	0.00094	0.00319	CcSEcCtD
Olopatadine—Nervous system disorder—Vinorelbine—ovarian cancer	0.000936	0.00317	CcSEcCtD
Olopatadine—Pain—Melphalan—ovarian cancer	0.000934	0.00317	CcSEcCtD
Olopatadine—Skin disorder—Vinorelbine—ovarian cancer	0.000927	0.00314	CcSEcCtD
Olopatadine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000923	0.00313	CcSEcCtD
Olopatadine—Feeling abnormal—Topotecan—ovarian cancer	0.000919	0.00312	CcSEcCtD
Olopatadine—Gastrointestinal pain—Topotecan—ovarian cancer	0.000912	0.00309	CcSEcCtD
Olopatadine—Rhinitis—Paclitaxel—ovarian cancer	0.000906	0.00307	CcSEcCtD
Olopatadine—Asthenia—Chlorambucil—ovarian cancer	0.000899	0.00305	CcSEcCtD
Olopatadine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000899	0.00305	CcSEcCtD
Olopatadine—Pharyngitis—Paclitaxel—ovarian cancer	0.000897	0.00304	CcSEcCtD
Olopatadine—Pruritus—Chlorambucil—ovarian cancer	0.000887	0.00301	CcSEcCtD
Olopatadine—Abdominal pain—Topotecan—ovarian cancer	0.000882	0.00299	CcSEcCtD
Olopatadine—Body temperature increased—Topotecan—ovarian cancer	0.000882	0.00299	CcSEcCtD
Olopatadine—Dry eye—Doxorubicin—ovarian cancer	0.000879	0.00298	CcSEcCtD
Olopatadine—Weight increased—Docetaxel—ovarian cancer	0.000871	0.00295	CcSEcCtD
Olopatadine—Visual impairment—Paclitaxel—ovarian cancer	0.000871	0.00295	CcSEcCtD
Olopatadine—Diarrhoea—Chlorambucil—ovarian cancer	0.000857	0.00291	CcSEcCtD
Olopatadine—Infestation NOS—Docetaxel—ovarian cancer	0.000853	0.00289	CcSEcCtD
Olopatadine—Infestation—Docetaxel—ovarian cancer	0.000853	0.00289	CcSEcCtD
Olopatadine—Dyspnoea—Vinorelbine—ovarian cancer	0.000851	0.00289	CcSEcCtD
Olopatadine—Eye disorder—Paclitaxel—ovarian cancer	0.000844	0.00286	CcSEcCtD
Olopatadine—Conjunctivitis—Docetaxel—ovarian cancer	0.000829	0.00281	CcSEcCtD
Olopatadine—Eye pain—Epirubicin—ovarian cancer	0.000827	0.00281	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000824	0.00279	CcSEcCtD
Olopatadine—Fatigue—Vinorelbine—ovarian cancer	0.000823	0.00279	CcSEcCtD
Olopatadine—Hypersensitivity—Topotecan—ovarian cancer	0.000822	0.00279	CcSEcCtD
Olopatadine—Pain—Vinorelbine—ovarian cancer	0.000816	0.00277	CcSEcCtD
Olopatadine—Immune system disorder—Paclitaxel—ovarian cancer	0.000816	0.00277	CcSEcCtD
Olopatadine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000814	0.00276	CcSEcCtD
Olopatadine—Hypersensitivity—Melphalan—ovarian cancer	0.000805	0.00273	CcSEcCtD
Olopatadine—Epistaxis—Docetaxel—ovarian cancer	0.000805	0.00273	CcSEcCtD
Olopatadine—Asthenia—Topotecan—ovarian cancer	0.0008	0.00271	CcSEcCtD
Olopatadine—Vomiting—Chlorambucil—ovarian cancer	0.000797	0.0027	CcSEcCtD
Olopatadine—Pruritus—Topotecan—ovarian cancer	0.000789	0.00268	CcSEcCtD
Olopatadine—Erythema—Paclitaxel—ovarian cancer	0.000786	0.00267	CcSEcCtD
Olopatadine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000786	0.00267	CcSEcCtD
Olopatadine—Asthenia—Melphalan—ovarian cancer	0.000784	0.00266	CcSEcCtD
Olopatadine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00078	0.00265	CcSEcCtD
Olopatadine—Pruritus—Melphalan—ovarian cancer	0.000773	0.00262	CcSEcCtD
Olopatadine—Dysgeusia—Paclitaxel—ovarian cancer	0.00077	0.00261	CcSEcCtD
Olopatadine—Rhinitis—Docetaxel—ovarian cancer	0.000768	0.0026	CcSEcCtD
Olopatadine—Eye pain—Doxorubicin—ovarian cancer	0.000765	0.0026	CcSEcCtD
Olopatadine—Diarrhoea—Topotecan—ovarian cancer	0.000763	0.00259	CcSEcCtD
Olopatadine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000762	0.00258	CcSEcCtD
Olopatadine—Back pain—Paclitaxel—ovarian cancer	0.000761	0.00258	CcSEcCtD
Olopatadine—Pharyngitis—Docetaxel—ovarian cancer	0.00076	0.00258	CcSEcCtD
Olopatadine—Muscle spasms—Paclitaxel—ovarian cancer	0.000756	0.00256	CcSEcCtD
Olopatadine—Body temperature increased—Vinorelbine—ovarian cancer	0.000754	0.00256	CcSEcCtD
Olopatadine—Abdominal pain—Vinorelbine—ovarian cancer	0.000754	0.00256	CcSEcCtD
Olopatadine—Diarrhoea—Melphalan—ovarian cancer	0.000747	0.00253	CcSEcCtD
Olopatadine—Nausea—Chlorambucil—ovarian cancer	0.000744	0.00252	CcSEcCtD
Olopatadine—Vision blurred—Paclitaxel—ovarian cancer	0.000741	0.00251	CcSEcCtD
Olopatadine—Visual impairment—Docetaxel—ovarian cancer	0.000738	0.0025	CcSEcCtD
Olopatadine—Dizziness—Topotecan—ovarian cancer	0.000738	0.0025	CcSEcCtD
Olopatadine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00073	0.00248	CcSEcCtD
Olopatadine—Eye disorder—Docetaxel—ovarian cancer	0.000716	0.00243	CcSEcCtD
Olopatadine—Vomiting—Topotecan—ovarian cancer	0.000709	0.00241	CcSEcCtD
Olopatadine—Malaise—Paclitaxel—ovarian cancer	0.000709	0.00241	CcSEcCtD
Olopatadine—Rash—Topotecan—ovarian cancer	0.000703	0.00239	CcSEcCtD
Olopatadine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000703	0.00238	CcSEcCtD
Olopatadine—Dermatitis—Topotecan—ovarian cancer	0.000703	0.00238	CcSEcCtD
Olopatadine—Headache—Topotecan—ovarian cancer	0.000699	0.00237	CcSEcCtD
Olopatadine—Vomiting—Melphalan—ovarian cancer	0.000694	0.00236	CcSEcCtD
Olopatadine—Immune system disorder—Docetaxel—ovarian cancer	0.000692	0.00235	CcSEcCtD
Olopatadine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00069	0.00234	CcSEcCtD
Olopatadine—Rash—Melphalan—ovarian cancer	0.000689	0.00234	CcSEcCtD
Olopatadine—Dermatitis—Melphalan—ovarian cancer	0.000688	0.00233	CcSEcCtD
Olopatadine—Cough—Paclitaxel—ovarian cancer	0.000686	0.00233	CcSEcCtD
Olopatadine—Asthenia—Vinorelbine—ovarian cancer	0.000685	0.00232	CcSEcCtD
Olopatadine—Dry skin—Epirubicin—ovarian cancer	0.000684	0.00232	CcSEcCtD
Olopatadine—Pruritus—Vinorelbine—ovarian cancer	0.000675	0.00229	CcSEcCtD
Olopatadine—Nasopharyngitis—Epirubicin—ovarian cancer	0.000668	0.00226	CcSEcCtD
Olopatadine—Erythema—Docetaxel—ovarian cancer	0.000667	0.00226	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000665	0.00226	CcSEcCtD
Olopatadine—Nausea—Topotecan—ovarian cancer	0.000663	0.00225	CcSEcCtD
Olopatadine—Discomfort—Paclitaxel—ovarian cancer	0.000662	0.00224	CcSEcCtD
Olopatadine—Dry mouth—Paclitaxel—ovarian cancer	0.000655	0.00222	CcSEcCtD
Olopatadine—Diarrhoea—Vinorelbine—ovarian cancer	0.000653	0.00221	CcSEcCtD
Olopatadine—Dysgeusia—Docetaxel—ovarian cancer	0.000653	0.00221	CcSEcCtD
Olopatadine—Nausea—Melphalan—ovarian cancer	0.000649	0.0022	CcSEcCtD
Olopatadine—Influenza—Epirubicin—ovarian cancer	0.000645	0.00219	CcSEcCtD
Olopatadine—Back pain—Docetaxel—ovarian cancer	0.000645	0.00219	CcSEcCtD
Olopatadine—Oedema—Paclitaxel—ovarian cancer	0.000642	0.00218	CcSEcCtD
Olopatadine—Muscle spasms—Docetaxel—ovarian cancer	0.000641	0.00217	CcSEcCtD
Olopatadine—Infection—Paclitaxel—ovarian cancer	0.000638	0.00216	CcSEcCtD
Olopatadine—Dry skin—Doxorubicin—ovarian cancer	0.000633	0.00215	CcSEcCtD
Olopatadine—Dizziness—Vinorelbine—ovarian cancer	0.000631	0.00214	CcSEcCtD
Olopatadine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000629	0.00214	CcSEcCtD
Olopatadine—Skin disorder—Paclitaxel—ovarian cancer	0.000623	0.00211	CcSEcCtD
Olopatadine—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000618	0.0021	CcSEcCtD
Olopatadine—Vomiting—Vinorelbine—ovarian cancer	0.000607	0.00206	CcSEcCtD
Olopatadine—Rash—Vinorelbine—ovarian cancer	0.000602	0.00204	CcSEcCtD
Olopatadine—Dermatitis—Vinorelbine—ovarian cancer	0.000601	0.00204	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.0006	0.00203	CcSEcCtD
Olopatadine—Headache—Vinorelbine—ovarian cancer	0.000598	0.00203	CcSEcCtD
Olopatadine—Influenza—Doxorubicin—ovarian cancer	0.000597	0.00203	CcSEcCtD
Olopatadine—Weight increased—Epirubicin—ovarian cancer	0.000587	0.00199	CcSEcCtD
Olopatadine—Cough—Docetaxel—ovarian cancer	0.000582	0.00197	CcSEcCtD
Olopatadine—Infestation NOS—Epirubicin—ovarian cancer	0.000575	0.00195	CcSEcCtD
Olopatadine—Infestation—Epirubicin—ovarian cancer	0.000575	0.00195	CcSEcCtD
Olopatadine—Dyspnoea—Paclitaxel—ovarian cancer	0.000572	0.00194	CcSEcCtD
Olopatadine—Somnolence—Paclitaxel—ovarian cancer	0.000571	0.00194	CcSEcCtD
Olopatadine—Nausea—Vinorelbine—ovarian cancer	0.000567	0.00192	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000564	0.00191	CcSEcCtD
Olopatadine—Conjunctivitis—Epirubicin—ovarian cancer	0.000559	0.0019	CcSEcCtD
Olopatadine—Urinary tract infection—Epirubicin—ovarian cancer	0.000559	0.0019	CcSEcCtD
Olopatadine—Dry mouth—Docetaxel—ovarian cancer	0.000555	0.00188	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000555	0.00188	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000554	0.00188	CcSEcCtD
Olopatadine—Fatigue—Paclitaxel—ovarian cancer	0.000553	0.00188	CcSEcCtD
Olopatadine—Pain—Paclitaxel—ovarian cancer	0.000549	0.00186	CcSEcCtD
Olopatadine—Oedema—Docetaxel—ovarian cancer	0.000544	0.00185	CcSEcCtD
Olopatadine—Weight increased—Doxorubicin—ovarian cancer	0.000543	0.00184	CcSEcCtD
Olopatadine—Epistaxis—Epirubicin—ovarian cancer	0.000543	0.00184	CcSEcCtD
Olopatadine—Infection—Docetaxel—ovarian cancer	0.00054	0.00183	CcSEcCtD
Olopatadine—Sinusitis—Epirubicin—ovarian cancer	0.00054	0.00183	CcSEcCtD
Olopatadine—Nervous system disorder—Docetaxel—ovarian cancer	0.000534	0.00181	CcSEcCtD
Olopatadine—Infestation NOS—Doxorubicin—ovarian cancer	0.000532	0.00181	CcSEcCtD
Olopatadine—Infestation—Doxorubicin—ovarian cancer	0.000532	0.00181	CcSEcCtD
Olopatadine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000529	0.00179	CcSEcCtD
Olopatadine—Skin disorder—Docetaxel—ovarian cancer	0.000528	0.00179	CcSEcCtD
Olopatadine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000525	0.00178	CcSEcCtD
Olopatadine—Rhinitis—Epirubicin—ovarian cancer	0.000518	0.00176	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—ovarian cancer	0.000517	0.00176	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000517	0.00176	CcSEcCtD
Olopatadine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000514	0.00174	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—ovarian cancer	0.000513	0.00174	CcSEcCtD
Olopatadine—Abdominal pain—Paclitaxel—ovarian cancer	0.000507	0.00172	CcSEcCtD
Olopatadine—Body temperature increased—Paclitaxel—ovarian cancer	0.000507	0.00172	CcSEcCtD
Olopatadine—Epistaxis—Doxorubicin—ovarian cancer	0.000502	0.0017	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—ovarian cancer	0.000499	0.00169	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—ovarian cancer	0.000498	0.00169	CcSEcCtD
Olopatadine—Dyspnoea—Docetaxel—ovarian cancer	0.000485	0.00165	CcSEcCtD
Olopatadine—Somnolence—Docetaxel—ovarian cancer	0.000484	0.00164	CcSEcCtD
Olopatadine—Eye disorder—Epirubicin—ovarian cancer	0.000483	0.00164	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—ovarian cancer	0.000479	0.00163	CcSEcCtD
Olopatadine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000475	0.00161	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—ovarian cancer	0.000474	0.00161	CcSEcCtD
Olopatadine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000473	0.0016	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00047	0.00159	CcSEcCtD
Olopatadine—Fatigue—Docetaxel—ovarian cancer	0.000469	0.00159	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—ovarian cancer	0.000467	0.00158	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000465	0.00158	CcSEcCtD
Olopatadine—Pain—Docetaxel—ovarian cancer	0.000465	0.00158	CcSEcCtD
Olopatadine—Visual impairment—Doxorubicin—ovarian cancer	0.000461	0.00156	CcSEcCtD
Olopatadine—Asthenia—Paclitaxel—ovarian cancer	0.000461	0.00156	CcSEcCtD
Olopatadine—Pruritus—Paclitaxel—ovarian cancer	0.000454	0.00154	CcSEcCtD
Olopatadine—Erythema—Epirubicin—ovarian cancer	0.00045	0.00153	CcSEcCtD
Olopatadine—Feeling abnormal—Docetaxel—ovarian cancer	0.000448	0.00152	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—ovarian cancer	0.000447	0.00151	CcSEcCtD
Olopatadine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000445	0.00151	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—ovarian cancer	0.00044	0.00149	CcSEcCtD
Olopatadine—Diarrhoea—Paclitaxel—ovarian cancer	0.000439	0.00149	CcSEcCtD
Olopatadine—Back pain—Epirubicin—ovarian cancer	0.000435	0.00148	CcSEcCtD
Olopatadine—Muscle spasms—Epirubicin—ovarian cancer	0.000432	0.00147	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—ovarian cancer	0.000432	0.00146	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000431	0.00146	CcSEcCtD
Olopatadine—Abdominal pain—Docetaxel—ovarian cancer	0.00043	0.00146	CcSEcCtD
Olopatadine—Body temperature increased—Docetaxel—ovarian cancer	0.00043	0.00146	CcSEcCtD
Olopatadine—Dizziness—Paclitaxel—ovarian cancer	0.000424	0.00144	CcSEcCtD
Olopatadine—Vision blurred—Epirubicin—ovarian cancer	0.000424	0.00144	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000417	0.00142	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—ovarian cancer	0.000416	0.00141	CcSEcCtD
Olopatadine—Vomiting—Paclitaxel—ovarian cancer	0.000408	0.00138	CcSEcCtD
Olopatadine—Dysgeusia—Doxorubicin—ovarian cancer	0.000407	0.00138	CcSEcCtD
Olopatadine—Malaise—Epirubicin—ovarian cancer	0.000405	0.00138	CcSEcCtD
Olopatadine—Rash—Paclitaxel—ovarian cancer	0.000405	0.00137	CcSEcCtD
Olopatadine—Dermatitis—Paclitaxel—ovarian cancer	0.000404	0.00137	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—ovarian cancer	0.000402	0.00137	CcSEcCtD
Olopatadine—Headache—Paclitaxel—ovarian cancer	0.000402	0.00136	CcSEcCtD
Olopatadine—Hypersensitivity—Docetaxel—ovarian cancer	0.000401	0.00136	CcSEcCtD
Olopatadine—Muscle spasms—Doxorubicin—ovarian cancer	0.0004	0.00136	CcSEcCtD
Olopatadine—Cough—Epirubicin—ovarian cancer	0.000392	0.00133	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—ovarian cancer	0.000392	0.00133	CcSEcCtD
Olopatadine—Asthenia—Docetaxel—ovarian cancer	0.00039	0.00132	CcSEcCtD
Olopatadine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000386	0.00131	CcSEcCtD
Olopatadine—Pruritus—Docetaxel—ovarian cancer	0.000385	0.00131	CcSEcCtD
Olopatadine—S100B—Innate Immune System—PPP2R1A—ovarian cancer	0.000385	0.000933	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PARK2—ovarian cancer	0.000382	0.000927	CbGpPWpGaD
Olopatadine—Nausea—Paclitaxel—ovarian cancer	0.000381	0.00129	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—KRAS—ovarian cancer	0.00038	0.000923	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00038	0.00129	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—ovarian cancer	0.000378	0.00128	CcSEcCtD
Olopatadine—Malaise—Doxorubicin—ovarian cancer	0.000375	0.00127	CcSEcCtD
Olopatadine—Dry mouth—Epirubicin—ovarian cancer	0.000374	0.00127	CcSEcCtD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000373	0.000906	CbGpPWpGaD
Olopatadine—Diarrhoea—Docetaxel—ovarian cancer	0.000372	0.00126	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—IL6—ovarian cancer	0.000369	0.000896	CbGpPWpGaD
Olopatadine—Oedema—Epirubicin—ovarian cancer	0.000367	0.00124	CcSEcCtD
Olopatadine—Infection—Epirubicin—ovarian cancer	0.000365	0.00124	CcSEcCtD
Olopatadine—Cough—Doxorubicin—ovarian cancer	0.000363	0.00123	CcSEcCtD
Olopatadine—S100B—Immune System—PARK2—ovarian cancer	0.000361	0.000877	CbGpPWpGaD
Olopatadine—Nervous system disorder—Epirubicin—ovarian cancer	0.00036	0.00122	CcSEcCtD
Olopatadine—Dizziness—Docetaxel—ovarian cancer	0.00036	0.00122	CcSEcCtD
Olopatadine—Skin disorder—Epirubicin—ovarian cancer	0.000356	0.00121	CcSEcCtD
Olopatadine—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000356	0.000863	CbGpPWpGaD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000352	0.00119	CcSEcCtD
Olopatadine—Discomfort—Doxorubicin—ovarian cancer	0.00035	0.00119	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—PIK3CA—ovarian cancer	0.000349	0.000848	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—DOK1—ovarian cancer	0.000349	0.000846	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—IL6—ovarian cancer	0.000348	0.000844	CbGpPWpGaD
Olopatadine—Dry mouth—Doxorubicin—ovarian cancer	0.000346	0.00117	CcSEcCtD
Olopatadine—Vomiting—Docetaxel—ovarian cancer	0.000346	0.00117	CcSEcCtD
Olopatadine—Rash—Docetaxel—ovarian cancer	0.000343	0.00116	CcSEcCtD
Olopatadine—Dermatitis—Docetaxel—ovarian cancer	0.000343	0.00116	CcSEcCtD
Olopatadine—Headache—Docetaxel—ovarian cancer	0.000341	0.00116	CcSEcCtD
Olopatadine—Oedema—Doxorubicin—ovarian cancer	0.00034	0.00115	CcSEcCtD
Olopatadine—Infection—Doxorubicin—ovarian cancer	0.000337	0.00114	CcSEcCtD
Olopatadine—S100A12—Immune System—IKBKG—ovarian cancer	0.000335	0.000813	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EREG—ovarian cancer	0.000335	0.000813	CbGpPWpGaD
Olopatadine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000333	0.00113	CcSEcCtD
Olopatadine—Skin disorder—Doxorubicin—ovarian cancer	0.00033	0.00112	CcSEcCtD
Olopatadine—S100B—Toll-Like Receptors Cascades—IL6—ovarian cancer	0.000329	0.000798	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PPP1CC—ovarian cancer	0.000328	0.000796	CbGpPWpGaD
Olopatadine—S100A12—Immune System—SKP2—ovarian cancer	0.000328	0.000795	CbGpPWpGaD
Olopatadine—Dyspnoea—Epirubicin—ovarian cancer	0.000327	0.00111	CcSEcCtD
Olopatadine—Somnolence—Epirubicin—ovarian cancer	0.000326	0.00111	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—HRAS—ovarian cancer	0.000323	0.000785	CbGpPWpGaD
Olopatadine—Nausea—Docetaxel—ovarian cancer	0.000323	0.0011	CcSEcCtD
Olopatadine—S100B—Immune System—EREG—ovarian cancer	0.000317	0.000769	CbGpPWpGaD
Olopatadine—S100B—Immune System—IKBKG—ovarian cancer	0.000317	0.000769	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000317	0.00107	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—ovarian cancer	0.000316	0.00107	CcSEcCtD
Olopatadine—Pain—Epirubicin—ovarian cancer	0.000314	0.00106	CcSEcCtD
Olopatadine—S100B—Immune System—SKP2—ovarian cancer	0.00031	0.000752	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—IL6—ovarian cancer	0.000309	0.000751	CbGpPWpGaD
Olopatadine—Dyspnoea—Doxorubicin—ovarian cancer	0.000303	0.00103	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—ovarian cancer	0.000302	0.00103	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—ovarian cancer	0.000302	0.00102	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.0003	0.00102	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—TLR4—ovarian cancer	0.000295	0.000717	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000293	0.000994	CcSEcCtD
Olopatadine—Fatigue—Doxorubicin—ovarian cancer	0.000293	0.000993	CcSEcCtD
Olopatadine—Pain—Doxorubicin—ovarian cancer	0.00029	0.000985	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—ovarian cancer	0.00029	0.000984	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—ovarian cancer	0.00029	0.000984	CcSEcCtD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000288	0.000698	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—AKT1—ovarian cancer	0.000286	0.000693	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000284	0.000689	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IL6ST—ovarian cancer	0.000283	0.000687	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—STAT3—ovarian cancer	0.000283	0.000687	CbGpPWpGaD
Olopatadine—Feeling abnormal—Doxorubicin—ovarian cancer	0.00028	0.000949	CcSEcCtD
Olopatadine—S100B—Innate Immune System—TLR4—ovarian cancer	0.000279	0.000678	CbGpPWpGaD
Olopatadine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000278	0.000942	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—MAPK3—ovarian cancer	0.000271	0.000657	CbGpPWpGaD
Olopatadine—Hypersensitivity—Epirubicin—ovarian cancer	0.00027	0.000917	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—ovarian cancer	0.000268	0.00091	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—ovarian cancer	0.000268	0.00091	CcSEcCtD
Olopatadine—S100B—Innate Immune System—IL6ST—ovarian cancer	0.000268	0.00065	CbGpPWpGaD
Olopatadine—Asthenia—Epirubicin—ovarian cancer	0.000263	0.000893	CcSEcCtD
Olopatadine—Pruritus—Epirubicin—ovarian cancer	0.00026	0.000881	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—MAPK1—ovarian cancer	0.000257	0.000625	CbGpPWpGaD
Olopatadine—Diarrhoea—Epirubicin—ovarian cancer	0.000251	0.000852	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—ovarian cancer	0.00025	0.000849	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—HDAC6—ovarian cancer	0.000248	0.000603	CbGpPWpGaD
Olopatadine—Asthenia—Doxorubicin—ovarian cancer	0.000244	0.000826	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—ovarian cancer	0.000243	0.000823	CcSEcCtD
Olopatadine—Pruritus—Doxorubicin—ovarian cancer	0.00024	0.000815	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—PIK3CD—ovarian cancer	0.000239	0.000581	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PPP2R1A—ovarian cancer	0.000237	0.000575	CbGpPWpGaD
Olopatadine—Vomiting—Epirubicin—ovarian cancer	0.000233	0.000791	CcSEcCtD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000233	0.000566	CbGpPWpGaD
Olopatadine—Diarrhoea—Doxorubicin—ovarian cancer	0.000232	0.000788	CcSEcCtD
Olopatadine—Rash—Epirubicin—ovarian cancer	0.000231	0.000785	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—ovarian cancer	0.000231	0.000784	CcSEcCtD
Olopatadine—Headache—Epirubicin—ovarian cancer	0.00023	0.00078	CcSEcCtD
Olopatadine—S100B—Innate Immune System—PIK3CD—ovarian cancer	0.000226	0.000549	CbGpPWpGaD
Olopatadine—Dizziness—Doxorubicin—ovarian cancer	0.000225	0.000762	CcSEcCtD
Olopatadine—S100B—Immune System—PPP2R1A—ovarian cancer	0.000224	0.000544	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—PIK3CA—ovarian cancer	0.000223	0.000542	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—YAP1—ovarian cancer	0.00022	0.000534	CbGpPWpGaD
Olopatadine—Nausea—Epirubicin—ovarian cancer	0.000218	0.000739	CcSEcCtD
Olopatadine—Vomiting—Doxorubicin—ovarian cancer	0.000216	0.000732	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—XIAP—ovarian cancer	0.000215	0.000523	CbGpPWpGaD
Olopatadine—Rash—Doxorubicin—ovarian cancer	0.000214	0.000726	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—ovarian cancer	0.000214	0.000725	CcSEcCtD
Olopatadine—Headache—Doxorubicin—ovarian cancer	0.000213	0.000721	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—ERBB2—ovarian cancer	0.000211	0.000513	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CD8A—ovarian cancer	0.000211	0.000512	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SMARCA4—ovarian cancer	0.00021	0.00051	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—MTOR—ovarian cancer	0.000209	0.000506	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PIK3CB—ovarian cancer	0.000209	0.000506	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EREG—ovarian cancer	0.000205	0.000497	CbGpPWpGaD
Olopatadine—Nausea—Doxorubicin—ovarian cancer	0.000202	0.000684	CcSEcCtD
Olopatadine—S100B—Innate Immune System—ERBB2—ovarian cancer	0.0002	0.000485	CbGpPWpGaD
Olopatadine—S100B—Immune System—CD8A—ovarian cancer	0.0002	0.000484	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—MTOR—ovarian cancer	0.000197	0.000479	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PIK3CB—ovarian cancer	0.000197	0.000479	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CDKN1B—ovarian cancer	0.000196	0.000475	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PGR—ovarian cancer	0.000192	0.000466	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CDKN1B—ovarian cancer	0.000185	0.000449	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—CTNNB1—ovarian cancer	0.000185	0.000449	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—AKT1—ovarian cancer	0.000182	0.000443	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PTEN—ovarian cancer	0.00018	0.000437	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PARP1—ovarian cancer	0.000179	0.000433	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HSD17B6—ovarian cancer	0.000178	0.000431	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—CTNNB1—ovarian cancer	0.000175	0.000424	CbGpPWpGaD
Olopatadine—S100A12—Immune System—TLR4—ovarian cancer	0.000172	0.000418	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PTEN—ovarian cancer	0.00017	0.000414	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6ST—ovarian cancer	0.000165	0.0004	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.000165	0.0004	CbGpPWpGaD
Olopatadine—S100B—Immune System—TLR4—ovarian cancer	0.000163	0.000395	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NRAS—ovarian cancer	0.000161	0.00039	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6ST—ovarian cancer	0.000156	0.000379	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—MAPK3—ovarian cancer	0.000154	0.000374	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—NRAS—ovarian cancer	0.000152	0.000369	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—DLC1—ovarian cancer	0.000151	0.000367	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—MAPK1—ovarian cancer	0.000147	0.000356	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—EGFR—ovarian cancer	0.000146	0.000356	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDH1—ovarian cancer	0.000146	0.000354	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—MAPK3—ovarian cancer	0.000146	0.000353	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PPP2R1A—ovarian cancer	0.000145	0.000351	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CD—ovarian cancer	0.000139	0.000338	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—MAPK1—ovarian cancer	0.000139	0.000336	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—EGFR—ovarian cancer	0.000139	0.000336	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—KRAS—ovarian cancer	0.000138	0.000336	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDH1—ovarian cancer	0.000138	0.000335	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CD—ovarian cancer	0.000132	0.00032	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—KRAS—ovarian cancer	0.000131	0.000318	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—PIK3CA—ovarian cancer	0.000127	0.000309	CbGpPWpGaD
Olopatadine—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	0.000124	0.000301	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—BCL9—ovarian cancer	0.000123	0.000299	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ERBB2—ovarian cancer	0.000123	0.000299	CbGpPWpGaD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000122	0.000296	CbGpPWpGaD
Olopatadine—S100A12—Immune System—MTOR—ovarian cancer	0.000121	0.000295	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CB—ovarian cancer	0.000121	0.000295	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—PIK3CA—ovarian cancer	0.00012	0.000292	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HRAS—ovarian cancer	0.000118	0.000285	CbGpPWpGaD
Olopatadine—S100B—Immune System—ERBB2—ovarian cancer	0.000116	0.000282	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TERT—ovarian cancer	0.000115	0.000279	CbGpPWpGaD
Olopatadine—S100B—Immune System—MTOR—ovarian cancer	0.000115	0.000279	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CB—ovarian cancer	0.000115	0.000279	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CDKN1B—ovarian cancer	0.000114	0.000277	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IL6—ovarian cancer	0.000113	0.000273	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL2—ovarian cancer	0.000112	0.000271	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HRAS—ovarian cancer	0.000111	0.00027	CbGpPWpGaD
Olopatadine—S100B—Immune System—CDKN1B—ovarian cancer	0.000108	0.000262	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CTNNB1—ovarian cancer	0.000108	0.000261	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IL6—ovarian cancer	0.000106	0.000258	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CAV1—ovarian cancer	0.000106	0.000258	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL2—ovarian cancer	0.000105	0.000256	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PTEN—ovarian cancer	0.000105	0.000255	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—AKT1—ovarian cancer	0.000104	0.000252	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ESR1—ovarian cancer	0.000103	0.000249	CbGpPWpGaD
Olopatadine—S100B—Immune System—CTNNB1—ovarian cancer	0.000102	0.000247	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6ST—ovarian cancer	0.000101	0.000245	CbGpPWpGaD
Olopatadine—S100B—Immune System—PTEN—ovarian cancer	9.93e-05	0.000241	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—AKT1—ovarian cancer	9.82e-05	0.000238	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—DOK1—ovarian cancer	9.74e-05	0.000236	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CG—ovarian cancer	9.69e-05	0.000235	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—APC—ovarian cancer	9.69e-05	0.000235	CbGpPWpGaD
Olopatadine—S100A12—Immune System—STAT3—ovarian cancer	9.39e-05	0.000228	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NRAS—ovarian cancer	9.36e-05	0.000227	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	9.35e-05	0.000227	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PPP1CC—ovarian cancer	9.16e-05	0.000222	CbGpPWpGaD
Olopatadine—S100A12—Immune System—MAPK3—ovarian cancer	8.97e-05	0.000218	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	8.96e-05	0.000217	CbGpPWpGaD
Olopatadine—S100B—Immune System—STAT3—ovarian cancer	8.88e-05	0.000215	CbGpPWpGaD
Olopatadine—S100B—Immune System—NRAS—ovarian cancer	8.86e-05	0.000215	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	8.63e-05	0.00021	CbGpPWpGaD
Olopatadine—S100A12—Immune System—MAPK1—ovarian cancer	8.53e-05	0.000207	CbGpPWpGaD
Olopatadine—S100A12—Immune System—EGFR—ovarian cancer	8.53e-05	0.000207	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	8.52e-05	0.000207	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	8.52e-05	0.000207	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CD—ovarian cancer	8.52e-05	0.000207	CbGpPWpGaD
Olopatadine—S100B—Immune System—MAPK3—ovarian cancer	8.48e-05	0.000206	CbGpPWpGaD
Olopatadine—HRH1—G alpha (q) signalling events—PIK3CA—ovarian cancer	8.27e-05	0.000201	CbGpPWpGaD
Olopatadine—S100B—Immune System—MAPK1—ovarian cancer	8.07e-05	0.000196	CbGpPWpGaD
Olopatadine—S100B—Immune System—EGFR—ovarian cancer	8.07e-05	0.000196	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KRAS—ovarian cancer	8.06e-05	0.000196	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	8.05e-05	0.000195	CbGpPWpGaD
Olopatadine—S100B—Immune System—KRAS—ovarian cancer	7.62e-05	0.000185	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NME2—ovarian cancer	7.55e-05	0.000183	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ERBB2—ovarian cancer	7.53e-05	0.000183	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MTOR—ovarian cancer	7.43e-05	0.00018	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CB—ovarian cancer	7.43e-05	0.00018	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CA—ovarian cancer	7.4e-05	0.00018	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	7.4e-05	0.00018	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL8—ovarian cancer	7.14e-05	0.000173	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CA—ovarian cancer	7e-05	0.00017	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1B—ovarian cancer	6.97e-05	0.000169	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HDAC6—ovarian cancer	6.94e-05	0.000168	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HRAS—ovarian cancer	6.85e-05	0.000166	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PPP2R1A—ovarian cancer	6.85e-05	0.000166	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	6.84e-05	0.000166	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CASP3—ovarian cancer	6.83e-05	0.000166	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL2—ovarian cancer	6.82e-05	0.000166	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCND1—ovarian cancer	6.65e-05	0.000161	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CTNNB1—ovarian cancer	6.58e-05	0.00016	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL8—ovarian cancer	6.57e-05	0.00016	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6—ovarian cancer	6.56e-05	0.000159	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	6.55e-05	0.000159	CbGpPWpGaD
Olopatadine—S100B—Immune System—HRAS—ovarian cancer	6.48e-05	0.000157	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MMP9—ovarian cancer	6.45e-05	0.000157	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTEN—ovarian cancer	6.42e-05	0.000156	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6—ovarian cancer	6.2e-05	0.00015	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—YAP1—ovarian cancer	6.14e-05	0.000149	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—ovarian cancer	6.05e-05	0.000147	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—XIAP—ovarian cancer	6.02e-05	0.000146	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SMARCA4—ovarian cancer	5.86e-05	0.000142	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VEGFA—ovarian cancer	5.8e-05	0.000141	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—STAT3—ovarian cancer	5.74e-05	0.000139	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NRAS—ovarian cancer	5.73e-05	0.000139	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EREG—ovarian cancer	5.72e-05	0.000139	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—ovarian cancer	5.72e-05	0.000139	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MAPK3—ovarian cancer	5.48e-05	0.000133	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PGR—ovarian cancer	5.36e-05	0.00013	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—ovarian cancer	5.33e-05	0.000129	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MAPK1—ovarian cancer	5.22e-05	0.000127	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EGFR—ovarian cancer	5.22e-05	0.000127	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CG—ovarian cancer	5.05e-05	0.000122	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PARP1—ovarian cancer	4.99e-05	0.000121	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KRAS—ovarian cancer	4.93e-05	0.00012	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYTB—ovarian cancer	4.87e-05	0.000118	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6ST—ovarian cancer	4.77e-05	0.000116	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CG—ovarian cancer	4.58e-05	0.000111	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CA—ovarian cancer	4.53e-05	0.00011	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CD—ovarian cancer	4.44e-05	0.000108	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—ovarian cancer	4.38e-05	0.000106	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—BRIP1—ovarian cancer	4.25e-05	0.000103	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	4.25e-05	0.000103	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HRAS—ovarian cancer	4.19e-05	0.000102	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PPP2R1A—ovarian cancer	4.04e-05	9.81e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CD—ovarian cancer	4.03e-05	9.78e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6—ovarian cancer	4.01e-05	9.73e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CB—ovarian cancer	3.87e-05	9.38e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL8—ovarian cancer	3.72e-05	9.02e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—ovarian cancer	3.7e-05	8.98e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—IL2—ovarian cancer	3.55e-05	8.62e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CB—ovarian cancer	3.51e-05	8.52e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL8—ovarian cancer	3.37e-05	8.19e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL2—ovarian cancer	3.22e-05	7.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TERT—ovarian cancer	3.21e-05	7.8e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CAV1—ovarian cancer	2.97e-05	7.21e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—ovarian cancer	2.86e-05	6.95e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—YAP1—ovarian cancer	2.85e-05	6.92e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6ST—ovarian cancer	2.82e-05	6.84e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APC—ovarian cancer	2.71e-05	6.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CG—ovarian cancer	2.71e-05	6.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—NRAS—ovarian cancer	2.71e-05	6.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MAPK3—ovarian cancer	2.59e-05	6.29e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MAPK1—ovarian cancer	2.47e-05	5.99e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EGFR—ovarian cancer	2.47e-05	5.99e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CD—ovarian cancer	2.38e-05	5.78e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CA—ovarian cancer	2.36e-05	5.72e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KRAS—ovarian cancer	2.33e-05	5.65e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—FASN—ovarian cancer	2.33e-05	5.64e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.29e-05	5.55e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.21e-05	5.36e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	2.14e-05	5.19e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.12e-05	5.14e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB2—ovarian cancer	2.1e-05	5.1e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MTOR—ovarian cancer	2.07e-05	5.03e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	2.07e-05	5.03e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL8—ovarian cancer	1.99e-05	4.84e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—HRAS—ovarian cancer	1.98e-05	4.81e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	1.95e-05	4.72e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	1.93e-05	4.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.91e-05	4.63e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL2—ovarian cancer	1.9e-05	4.62e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.9e-05	4.6e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.88e-05	4.56e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.86e-05	4.51e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.84e-05	4.46e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.8e-05	4.38e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.79e-05	4.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.75e-05	4.24e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.74e-05	4.23e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TYMS—ovarian cancer	1.71e-05	4.16e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.62e-05	3.93e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.6e-05	3.89e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.6e-05	3.88e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.53e-05	3.72e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.49e-05	3.61e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.46e-05	3.54e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.46e-05	3.54e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CAV1—ovarian cancer	1.38e-05	3.35e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.38e-05	3.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	1.26e-05	3.07e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.26e-05	3.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—ovarian cancer	1.22e-05	2.97e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HRAS—ovarian cancer	1.17e-05	2.84e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6—ovarian cancer	1.12e-05	2.72e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.11e-05	2.68e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—ovarian cancer	1.03e-05	2.51e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	9.63e-06	2.34e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTEN—ovarian cancer	8.33e-06	2.02e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.87e-06	1.43e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—ovarian cancer	4.8e-06	1.16e-05	CbGpPWpGaD
